Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Abstract: This article introduces a hybrid Slepian beamforming receiver architecture with low power and area costs. Traditional large-scale true-time-delay (TTD) beamformers for wideband wireless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results